Tvardi Therapeutics, Inc. (TVRD) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Tvardi Therapeutics, Inc. (TVRD) has a cash flow conversion efficiency ratio of -0.153x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.26 Million) by net assets ($27.87 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Tvardi Therapeutics, Inc. - Cash Flow Conversion Efficiency Trend (2020–2024)
This chart illustrates how Tvardi Therapeutics, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Read TVRD total debt and obligations for a breakdown of total debt and financial obligations.
Tvardi Therapeutics, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Tvardi Therapeutics, Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Shengli Oil & Gas Pipe Holdings Limited
F:GSG
|
-0.162x |
|
HICL Infrastructure Company Ltd
LSE:HICL
|
0.008x |
|
Bintai Kinden Corporation Bhd
KLSE:6998
|
-0.082x |
|
Elon AB (publ)
ST:ELON
|
0.175x |
|
Norse Atlantic ASA
OL:NORSE
|
-0.032x |
|
Shaftesbury Capital PLC
LSE:SHC
|
0.010x |
|
International Public Partnership
LSE:INPP
|
0.025x |
|
Churchill Resources Inc
V:CRI
|
-0.401x |
Annual Cash Flow Conversion Efficiency for Tvardi Therapeutics, Inc. (2020–2024)
The table below shows the annual cash flow conversion efficiency of Tvardi Therapeutics, Inc. from 2020 to 2024. For the full company profile with market capitalisation and key ratios, see Tvardi Therapeutics, Inc. market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-4.59 Million | $-60.92 Million | 13.263x | +3811.96% |
| 2023-12-31 | $-62.06 Million | $-21.04 Million | 0.339x | -14.51% |
| 2022-12-31 | $-45.05 Million | $-17.87 Million | 0.397x | +250.16% |
| 2021-12-31 | $227.52 Million | $-60.09 Million | -0.264x | -1098.46% |
| 2020-12-31 | $249.00 Million | $-5.49 Million | -0.022x | -- |
About Tvardi Therapeutics, Inc.
Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting STAT3 to treat fibrosis-driven diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 2 clinical development stage for fibrosis-driven diseases with an initial focus on … Read more